Brain & Diabetes: New Treatment Target?
- A new study in the Journal of Clinical Investigation suggests that successfully treating type 2 diabetes treatment may depend on targeting brain neurons,rather than solely focusing on obesity...
- Dr. Michael Schwartz, an endocrinologist at UW Medicine and the paper's corresponding author, stated that these neurons have an "outsized role in hyperglycemia and type 2 diabetes."
- To investigate the role of these neurons in elevated blood sugar, researchers used viral genetics to prevent AgRP neurons from communicating with other neurons in diabetic mice.
Targeting brain neurons could revolutionize type 2 diabetes treatment, according to a groundbreaking study. Researchers discovered that a specific group of neurons, AgRP neurons, in the hypothalamus play a significant role in managing blood sugar. Their findings suggest that this approach—a new way to approach diabetes treatment—may be effective, even absent changes in weight.Traditional methods often focus on obesity and insulin resistance, but this research offers a different viewpoint. This divergence from the conventional understanding makes this finding a pivotal shift. Drugs, such as Ozempic, may already be inhibiting these key neurons, offering a potential connection to existing treatments. News Directory 3 recognizes the potential of this research. discover what’s next for diabetes treatment in the coming studies.
Brain Neurons key to Type 2 Diabetes Treatment,Study Finds
Updated June 06,2025
A new study in the Journal of Clinical Investigation suggests that successfully treating type 2 diabetes treatment may depend on targeting brain neurons,rather than solely focusing on obesity or insulin resistance. Researchers have observed that a subset of neurons in the hypothalamus, known as AgRP neurons, are often hyperactive in mice with type 2 diabetes.
Dr. Michael Schwartz, an endocrinologist at UW Medicine and the paper’s corresponding author, stated that these neurons have an “outsized role in hyperglycemia and type 2 diabetes.”
To investigate the role of these neurons in elevated blood sugar, researchers used viral genetics to prevent AgRP neurons from communicating with other neurons in diabetic mice. Surprisingly, this intervention normalized high blood sugar for months, even without affecting body weight or food consumption.
Conventional understanding links type 2 diabetes to genetic predisposition and lifestyle factors like obesity, inactivity, and poor diet, leading to insulin resistance or insufficient insulin production. Schwartz noted that scientists have traditionally overlooked the brain’s role in type 2 diabetes.
Schwartz said the paper challenges this view and marks a “departure from the conventional wisdom of what causes diabetes.”
These findings align with previous studies by the same team, which showed that injecting a peptide called FGF1 directly into the brain also induced diabetes remission in mice by inhibiting AgRP neurons.
The researchers’ report indicates that while these neurons are crucial for controlling blood sugar in diabetes, they do not considerably contribute to obesity in the studied mice. in essence, targeting these neurons may lead to diabetes remission without reversing obesity, according to Schwartz.
Schwartz emphasized the need for further research to understand how to regulate the activity of these neurons and why they become hyperactive. answering these questions could pave the way for therapeutic approaches to calm them down.
This approach could shift how clinicians understand and treat this chronic disease. Schwartz pointed out that drugs like Ozempic, used for type 2 diabetes, also inhibit AgRP neurons, though the extent of this effect on their antidiabetic action remains unclear. Further research could clarify the role of AgRP neurons in normal blood sugar control and perhaps translate these findings into human clinical trials.
What’s next
Future studies will focus on understanding the mechanisms that cause AgRP neurons to become hyperactive and exploring therapeutic strategies to regulate their activity,potentially leading to new treatments for type 2 diabetes.